A detailed history of Jacobs Levy Equity Management, Inc transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 143,679 shares of ADPT stock, worth $801,728. This represents 0.0% of its overall portfolio holdings.

Number of Shares
143,679
Holding current value
$801,728
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.37 - $5.12 $484,198 - $735,636
143,679 New
143,679 $735,000
Q4 2023

Feb 14, 2024

BUY
$3.46 - $5.33 $1.48 Million - $2.29 Million
428,858 New
428,858 $2.1 Million
Q2 2023

Aug 14, 2023

SELL
$6.19 - $8.78 $38,278 - $54,295
-6,184 Reduced 10.83%
50,930 $341,000
Q1 2023

May 15, 2023

SELL
$7.8 - $10.11 $185,242 - $240,102
-23,749 Reduced 29.37%
57,114 $504,000
Q4 2022

Feb 14, 2023

SELL
$6.26 - $9.34 $218,868 - $326,554
-34,963 Reduced 30.19%
80,863 $617,000
Q3 2022

Nov 15, 2022

BUY
$6.5 - $12.67 $752,869 - $1.47 Million
115,826 New
115,826 $825,000
Q3 2021

Nov 15, 2021

SELL
$30.02 - $39.87 $443,485 - $588,999
-14,773 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$32.22 - $44.59 $142,895 - $197,756
4,435 Added 42.9%
14,773 $604,000
Q1 2021

May 17, 2021

SELL
$37.26 - $67.74 $1.13 Million - $2.05 Million
-30,227 Reduced 74.51%
10,338 $416,000
Q4 2020

Feb 16, 2021

SELL
$45.01 - $65.47 $40,373 - $58,726
-897 Reduced 2.16%
40,565 $2.4 Million
Q3 2020

Nov 16, 2020

BUY
$35.79 - $48.81 $564,193 - $769,440
15,764 Added 61.34%
41,462 $2.02 Million
Q2 2020

Aug 17, 2020

BUY
$24.95 - $48.38 $641,165 - $1.24 Million
25,698 New
25,698 $1.24 Million

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $797M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.